HQY

Analyst Note: HQY (HealthEquity, Inc.)

Date: 2026-06-13 Current Price: $85.21

1. Structural Readiness

• State: Context-only
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 3.7% (Productive)

Setup Classification: FORMING (Context-Only)

2. Thesis Layer

Tactical, Setup-Led Name. There is no named secular thesis attached to this specific setup at this date. While the broader HSA market is expanding, the investment case for HQY as of 2026-06-13 is driven strictly by setup quality and business fundamentals rather than a specific macro or thematic thesis. The conviction must be derived from the strength of the earnings guidance, the market share data, and the structural formation of the price action, not from an external narrative.

3. The Business

HealthEquity, Inc. operates as a technology-powered service platform for Health Savings Accounts (HSAs) and related healthcare financial products. The company serves both individual consumers and employers (Clients) across the United States.

Business Model & Revenue Sources: The company generates revenue from three primary streams:

• Service Revenue: Fees for platform usage, marketplace access, and advisory services.
• Custodial Revenue: Interest income on HSA cash balances (yield-dependent).
• Interchange Revenue: Fees from card transactions.

Key Operational Metrics (as of 2026-06-13):

• Asset Growth: As of April 30, 2026, the company administered 10.6 million HSAs with balances totaling $37.1 billion in HSA Assets, alongside 7.2 million complementary CDBs (E8).
• Market Share: The company has increased its share of the HSA market from 4% in December 2010 to 20% as of December 2025, measured by HSA Assets (E14). As of June 2025, it was the largest HSA provider by number of accounts and the second largest by assets (E19).
• New Account Acquisition: In Q1 2026, new HSAs from sales grew 15%, introducing 172,000 new accounts (E2).
• Strategic Acquisitions: In fiscal 2025, the company acquired the BenefitWallet HSA portfolio (approx. 616,000 HSAs, $2.7 billion in assets) from Conduent for $425.0 million (E20).
• Regulatory Tailwinds: The "One Big Beautiful Bill Act" (signed July 2025) expanded HSA eligibility to individuals with Bronze and Catastrophic plans, broadening the addressable market (E13).

Financial Guidance (FY 2026): Management expects revenue between $1.41 billion and $1.42 billion. They project GAAP net income of $242 million to $248 million ($2.88–$2.95 per share) and non-GAAP net income of $392 million to $398 million ($4.66–$4.73 per share) (E1). Adjusted EBITDA is expected between $625 million and $633 million (E1).

4. Archetype and Conviction

Archetype: Quality Compounder The name fits the "Quality Compounder" archetype based on the following evidence:

• Margin Inflector: Management expects service costs to decrease on an annual basis as operational efficiencies offset the costs of increasing total accounts (E15).
• Yield Sensitivity: The company expects custodial revenue to increase as existing cash contracts are renewed or replaced with higher-rate agreements, assuming the interest rate environment continues (E11).
• Market Leadership: With 20% market share and a history of outperforming market growth (8% HSA growth vs. 6% market growth in 2025), the company demonstrates a compounding ability to capture market share (E4).
• Valuation Context: The financial spine indicates a forward consensus EPS of $3.96 for FY1 and $4.72 for FY2 (E29).

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm strong growth, market share gains, and clear guidance.
• Structural Quality: Moderate to High. The company is a market leader with a clear moat (network effects via 200+ network partners) and a growing asset base.
• Rerating Potential: Moderate. The combination of regulatory expansion (E13) and yield recovery (E11) provides a logical path for multiple expansion if the breakout confirms.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Continued Asset Growth: Reporting HSA asset growth exceeding the 19% Q1 2026 rate in subsequent quarters would reinforce the compounding narrative.
• Yield Expansion: Confirmation that the "Enhanced Rates" offering is successfully capturing higher yields, boosting custodial revenue (E21).

What Would Invalidate the Case:

• Market Share Erosion: A decline in HSA asset growth or market share relative to competitors would challenge the "Quality Compounder" status.
• Regulatory Reversal: Any legislative changes reversing the "One Big Beautiful Bill Act" provisions would remove a key growth driver.

Gaps in Evidence:

• Capex/Lead Times: No specific data on capital expenditure plans or lead times for new product rollouts (e.g., the diagnostics expansion mentioned in E5) is provided in the evidence block.
• Competitor Specifics: While Devenir market growth is cited (E4), specific competitor financials or market share shifts are not detailed beyond the general 20% share stat.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key risks: 1) Failure to break out above resistance (setup remains forming); 2) Interest rate environment deteriorating faster than expected, reducing custodial yield; 3) Operational inefficiencies failing to offset account growth costs; 4) Regulatory changes reversing recent HSA expansions. Sizing hint: Position size should reflect the "forming" nature of the setup; allocate based on the probability of a breakout rather than a confirmed trend. Expected path: Management expects service revenue to increase via marketplace and investment growth, while custodial revenue rises with rate renewals; structural implications suggest continued asset accumulation if the breakout confirms. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.